Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
Kite, a Gilead Company (Nasdaq: GILD), today announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy. ZUMA-3 is a single-arm Phase 1/2 study in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The results provide guidance on dosing and safety management for KTE-X19 to inform the ongoing Phase 2 study. The data were presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 – June 4 (Abstract #7006).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190601005017/en/
By the end of Phase 1, 45 patients received KTE-X19 at one of three different doses levels [2 x 106 cells/kg (n=6), 1 x 106 cells/kg (n=23), or 0.5 x 106 cells/kg (n=16)]. Patients enrolled in this study were primary refractory or relapsed/refractory after at least two prior lines of therapy. Of 41 patients who were evaluable for efficacy after a minimum two months of follow-up (median follow-up of 16 months), 68 percent achieved complete response (CR) or CR with incomplete hematological recovery (CRi) and 100 percent of responders had undetectable minimal residual disease (MRD). Of the 23 patients treated with the dose level that will be used in the ongoing Phase 2 study (1 x 106 cells/kg), 19 were evaluable for efficacy. At the time of data cut-off (median duration of remission = 12.9 months), 16 (84 percent) patients achieved CR or CRi, and 12 patients (75 percent) were in ongoing response.
No dose-limiting toxicities (DLTs) were identified. Grade ≥3 cytokine release syndrome (CRS) events and neurologic events occurred in 29 percent and 38 percent of all patients, respectively. As previously reported, two patients experienced KTE-X19–related Grade 5 adverse events (AEs) during the study; one developed stroke in the context of CRS and neurologic events, and one experienced multiorgan failure secondary to CRS. Among patients receiving 1 x 106 cell/kg (n=23), 26 percent experienced Grade ≥3 CRS, and 43 percent experienced Grade ≥3 neurologic events.
A revised AE management protocol was implemented in nine patients treated with 1 x106 cells/kg of KTE-X19 during the study. In this revised protocol, corticosteroids were initiated at onset of Grade ≥2 neurologic events (versus previous onset of Grade 3) and tocilizumab was only given for management of toxicities in the context of CRS (versus prophylactic administration in Cohort 2). Of those patients, two (22 percent) had Grade 3 CRS and one (11 percent) had Grade 3 neurologic events. There were no Grade 4/5 events.
“Adults with relapsed or refractory ALL represent an extremely difficult-to-treat patient population,” said Bijal Shah, MD, ZUMA-3 investigator and medical oncologist, Moffitt Cancer Center, Tampa, Florida. “We’re encouraged by the high response rates in this study, as well as the reduced incidence and severity of CRS and neurologic events that were observed following implementation of the revised safety management protocol. We are now evaluating the use of KTE-X19 at the selected dose with this safety management protocol in the ongoing ZUMA-3 Phase 2 study.”
“The completion of the Phase 1 portion of the ZUMA-3 trial is an important milestone for our second investigational CAR T cell therapy,” said John McHutchison, AO, MD, Chief Scientific Officer, Head of Research and Development, Gilead. “We are pleased with the high response rates observed with KTE-X19 in this trial, and the progress of our broader effort aimed to further improve the benefit/risk profile of CAR T therapy through the investigation of novel safety management approaches.”
This abstract has also been selected to be included in the 2019 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.
KTE-X19 is an investigational therapy that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for any uses. Efficacy and safety have not been established.
ALL is an aggressive type of blood cancer which can also involve the lymph nodes, spleen, liver, central nervous system and other organs.
ZUMA-3 is an ongoing multicenter, registrational Phase 1/2 study in adult patients (≥18 years old) with ALL whose disease is refractory to or has relapsed following standard chemotherapy or hematopoietic stem cell transplantation. The objectives of the study are to evaluate the safety and efficacy of KTE-X19 in this patient population.
KTE-X19 is an investigational CD19 CAR T cell therapy. KTE-X19 has the same construct as axicabtagene ciloleucel; however, the manufacturing process for KTE-X19 differs from that of axicabtagene ciloleucel and includes the enrichment of lymphocytes. Lymphocyte enrichment is necessary in certain B-cell malignancies for which KTE-X19 in under investigation. KTE-X19 is currently in Phase 1/2 trials in acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Kite’s ability to complete Phase 2 of the ZUMA-3 study of KTE-X19 in adult patients with relapsed or refractory acute lymphoblastic leukemia in the currently anticipated timelines, or at all. In addition, there is the possibility of unfavorable results from other ongoing and additional clinical trials involving KTE-X19. Further, Kite may be unable to obtain regulatory approval for KTE-X19 from the FDA or other regulatory authorities. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation to update any such forward-looking statements.
For more information on Kite, please visit the company’s website at www.kitepharma.com . Learn more about Gilead at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-300
Sung Lee, Investors
Nathan Kaiser, Media
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acrisure and Tulco Unveil Altway Insurance19.9.2019 16:00:00 CEST | Press release
Top 10 global insurance broker Acrisure and leading investment company Tulco Holdings unveils Altway Insurance, a direct-to-consumer brokerage platform which is fully supported by artificial intelligence. Altway Insurance represents a unique blend of a world-class AI firm matched with an insurance broker with an equally world-class distribution network. Additionally, Google Cloud is working closely with the company on how to integrate Google's most cutting-edge AI technology into new AI applications. Tulco Chairman and CEO Thomas Tull said, “While there has been substantial investment to fuse technology and insurance, today, there remains a massive and unmet opportunity to truly create the broker of the future. To meet that opportunity, we're thrilled to combine the AI and analytics leadership of Tulco with the phenomenal growth and global distribution power of Acrisure.” Underlying Altway is the unique combination of Acrisure and Tulco. Acrisure delivers high quality insurance service
Mindbreeze recognized once again as a Leader in the 2019 Gartner Magic Quadrant for Insight Engines19.9.2019 15:20:00 CEST | Press release
Mindbreeze, a leading global provider of appliances and cloud services for information insight and applied artificial intelligence with a focus on knowledge management for international companies, announced today that the company has been positioned by Gartner, Inc. as a Leader in the 2019 Magic Quadrant for Insight Engines. A complimentary copy of the report can be accessed from the Mindbreeze website “Mindbreeze enables our customers and their employees to garner and leverage crucial insights from their data. We work directly with our customers in this innovative field to bring meaning and value to their information assets that take us to the next level together,” comments Daniel Fallmann, Mindbreeze CEO and founder. “We believe this recognition further validates Mindbreeze’s success in the AI and knowledge management industry, as enterprises achieve ideal results using our unique and innovative solution.” Download the 2019 Magic Quadrant for Insight Engines now Many well-known custo
Amazon Co-founds The Climate Pledge, Setting Goal to Meet the Paris Agreement 10 Years Early19.9.2019 15:15:00 CEST | Press release
Today, Amazon (NASDAQ: AMZN) and Global Optimism announced The Climate Pledge, a commitment to meet the Paris Agreement 10 years early. Amazon today becomes the first signatory of this pledge. The Climate Pledge calls on signatories to be net zero carbon across their businesses by 2040—a decade ahead of the Paris Accord’s goal of 2050. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190919005609/en/ Companies that sign The Climate Pledge agree to: Measure and report greenhouse gas emissions on a regular basis; Implement decarbonization strategies in line with the Paris Agreement through real business changes and innovations, including efficiency improvements, renewable energy, materials reductions, and other carbon emission elimination strategies; Neutralize any remaining emissions with additional, quantifiable, real, permanent, and socially-beneficial offsets to achieve net zero annual carbon emissions by 2040. “We’re done b
In Impact Investing First, LeapFrog Announces Audit on Impact Principles, Achieving Top Rating19.9.2019 15:02:00 CEST | Press release
LeapFrog Investments today became the first impact investor globally to announce the results of an independent audit of its impact against the Operating Principles for Impact Management, new industry standards developed by the IFC in consultation with leading impact investors and other stakeholders. Launched in April, the Principles provide common disciplines for management of investments for impact, helping to ensure authenticity and high standards of measurement. In the independent audit by Tideline, a leading US impact advisory consultancy, LeapFrog was assessed as an “Exemplification of industry best practice,” with its Impact Measurement and Management (IMM) system achieving “an advanced level of alignment across the board for all nine of the Principles.” Tideline concluded that “LeapFrog’s IMM comprehensively addresses and exceeds the implementation guidance provided by the IFC and has been refined and strengthened over the course of several funds.” “The impact investing industry
Andersen Global Expands Reach in London19.9.2019 13:30:00 CEST | Press release
Andersen Global continues its expansion in the UK as Miles Dean, Zoe Wyatt and their team join the Andersen Tax LLP team in the UK. This addition brings further depth to the group in London and enhances the team’s ability to work with clients holistically and provide best-in-class, seamless service. Andersen Global has a presence in five locations in the UK through its member and collaborating firms. Miles and Zoe previously worked at Milestone which was founded by Miles Dean in 2008, with Zoe Wyatt joining as a partner in 2015. As part of Andersen Tax LLP, these partners will continue to provide a broad range of international tax services to corporations and private clients, investment funds and real estate investors and developers. Milestone signed a collaboration agreement with Andersen Global in 2018 and the positive impact of this relationship has led to Miles, Zoe and their team now joining the Andersen Global member firm in the UK. “It was so important to us to ensure we are pos
CGLytics and Glass Lewis Set a New Standard for Transparency in Equity-based Compensation19.9.2019 13:15:00 CEST | Press release
CGLytics, a leading global provider of governance data and analytics, and Glass Lewis, the world’s leading independent provider of governance and engagement support services, today announced the launch of Glass Lewis’ Equity Compensation Model (ECM) - a powerful new application for assessing U.S. equity-based compensation plans, available exclusively via CGLytics. This new application provides invaluable intelligence with year-round, on-demand access to Glass Lewis’ methodology which is used to evaluate the overall favorability of current and future equity plans, including tests against 11 key criteria. Companies and investors can now instantly test, review and adjust the same individual inputs as Glass Lewis’ analysts to ensure the best compensation, engagement and voting outcomes for their respective sides. The ECM provides companies with immediate and proactive insight into the concerns regarding current and future equity plans, which Glass Lewis highlights to more than 1,300 invest